Clincosm LogoSign in Get a demo

Relapsing-remitting Multiple Sclerosis

Showing 26 - 50 of 119
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing-Remitting Multiple Sclerosis Trial in United States (Glatiramer acetate)

Completed
Has Results
  • Relapsing-Remitting Multiple Sclerosis
  • Glatiramer acetate
  • Los Angeles, California
  • +10 more
Feb 14, 2020

Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Trial in Barcelona (XCEL-MC-ALPHA, Placebo)

Completed
  • Relapsing-Remitting Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Barcelona, Spain
    Hospital Vall Hebron
Jan 15, 2020

Relapsing-remitting Multiple Sclerosis Trial in Worldwide (BAF312, Placebo)

Completed
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Cullman, Alabama
  • +71 more
Dec 26, 2019

Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis Trial in Worldwide (BIIB019 (Daclizumab))

Terminated
Has Results
  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis
  • BIIB019 (Daclizumab)
  • Phoenix, Arizona
  • +221 more
Nov 11, 2019

Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis Trial

Unknown status
  • Relapsing-remitting Multiple Sclerosis
  • +2 more
  • Los Angeles, California
  • +3 more
Nov 4, 2019

Relapsing-Remitting Multiple Sclerosis, Urinary Incontinence Trial in Villalba (Pelvic floor exercises guided by a

Completed
  • Relapsing-Remitting Multiple Sclerosis
  • Urinary Incontinence
  • Pelvic floor exercises guided by a physiotherapist
  • Non guided pelvic floor exercises
  • Villalba, Madrid, Spain
    Hospital General de Villalba
Jul 9, 2019

Mitochondrial Dysfunction and Disease Progression

Completed
  • Clinically Isolated Syndrome
  • +3 more
    • New York, New York
      Icahn School of Medicine
    Feb 19, 2019

    Tysabri in Early Relapsing-Remitting Multiple Sclerosis in

    Completed
    • Relapsing-Remitting Multiple Sclerosis
    • natalizumab
    • Homewood, Alabama
    • +43 more
    Feb 11, 2019

    Relapsing-remitting Multiple Sclerosis Trial in Germany (fingolimod)

    Completed
    Has Results
    • Relapsing-remitting Multiple Sclerosis
    • Ostfildern, Baden-Wuerttemberg, Germany
    • +25 more
    Sep 6, 2018

    Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis Trial (PET with [11C]Flumazenil)

    Unknown status
    • Multiple Sclerosis
    • Relapsing-Remitting Multiple Sclerosis
    • PET with [11C]Flumazenil
    • (no location specified)
    Jan 30, 2019

    Clinical Disease Activity With Long Term Natalizumab Treatment

    Completed
    • Relapsing-Remitting Multiple Sclerosis
    • Brussels, Belgium
    • +3 more
    Jan 3, 2019

    Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis Trial in Worldwide (Placebo, dimethyl fumarate)

    Completed
    • Relapsing-Remitting Multiple Sclerosis
    • Multiple Sclerosis
    • Placebo
    • dimethyl fumarate
    • Brno, Czechia
    • +53 more
    Nov 19, 2018

    Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (LY2127399, Placebo)

    Completed
    Has Results
    • Relapsing-Remitting Multiple Sclerosis
    • Phoenix, Arizona
    • +62 more
    Nov 10, 2018

    Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (BIIB019 (Daclizumab), trivalent seasonal influenza vaccine)

    Completed
    Has Results
    • Relapsing-Remitting Multiple Sclerosis
    • BIIB019 (Daclizumab)
    • trivalent seasonal influenza vaccine
    • Brno, Czechia
    • +64 more
    Apr 11, 2018

    Tysabri (BG00002) Over 12 Months on MS Related Fatigue in RRMS

    Completed
    • Relapsing-Remitting Multiple Sclerosis
    • Fatigue
    • Natalizumab
    • Graz, Austria
    • +26 more
    Nov 6, 2018

    Rebif and Tecfidera on Infections and Lymphocytes

    Completed
    • Relapsing-Remitting Multiple Sclerosis
      • Foxboro, Massachusetts
        Neurology Center of New England
      Aug 3, 2018

      Relapsing-remitting Multiple Sclerosis Trial in Worldwide (Rebif®, Copaxone®)

      Completed
      Has Results
      • Relapsing-remitting Multiple Sclerosis
      • Birmingham, Alabama
      • +79 more
      Sep 15, 2017

      Ireland Natalizumab (TYSABRI) Observational Program

      Completed
      • Relapsing-Remitting Multiple Sclerosis
      • natalizumab
      • Cork, County Cork, Ireland
      • +4 more
      May 3, 2018

      Relapsing-Remitting Multiple Sclerosis Trial in Napoli (Vitamin K Cream, Placebo Cream)

      Completed
      • Relapsing-Remitting Multiple Sclerosis
      • Vitamin K Cream
      • Placebo Cream
      • Napoli, Italy
        Research Site
      Apr 4, 2018

      Patient Real-world Clinical, Neurological, Tolerability, and

      Completed
      • Relapsing-remitting Multiple Sclerosis
      • Birmingham, Alabama
      • +22 more
      Feb 28, 2018

      Oral Molecules Preventing Relapses in Multiple Sclerosis

      Completed
      • Relapsing-remitting Multiple Sclerosis
      • Non interventional study
      • Nantes, France
        Nantes University Hospital
      Oct 2, 2017

      Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (natalizumab, fingolimod)

      Terminated
      Has Results
      • Relapsing-Remitting Multiple Sclerosis
      • Aurora, Colorado
      • +41 more
      May 17, 2017

      Relapsing-Remitting Multiple Sclerosis Trial in Germany (dimethyl fumarate)

      Completed
      Has Results
      • Relapsing-Remitting Multiple Sclerosis
      • dimethyl fumarate
      • Augsburg, Germany
      • +18 more
      Mar 7, 2017

      Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis Trial in United States (dimethyl fumarate)

      Completed
      Has Results
      • Relapsing-Remitting Multiple Sclerosis
      • Multiple Sclerosis
      • dimethyl fumarate
      • Gilbert, Arizona
      • +15 more
      Feb 14, 2017

      Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive, Relapsing-Remitting Multiple Sclerosis Trial

      Completed
      • Multiple Sclerosis, Remittent Progressive
      • +4 more
      • Placebo
      • BIIB041 (fampridine)
      • Bunkyo-ku, Japan
      • +18 more
      Mar 17, 2017